Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS

This study has been completed.
Sponsor:
Collaborator:
Forest Laboratories
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00887679
First received: April 23, 2009
Last updated: October 23, 2014
Last verified: March 2014
Results First Received: November 19, 2012  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Anxiety Disorders
HIV Infections
Intervention: Drug: Escitalopram

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Anxiety disorders in HIV-infected patients from the general population

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Escitalopram Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.

Participant Flow:   Overall Study
    Escitalopram
STARTED   30 
COMPLETED   20 [1] 
NOT COMPLETED   10 
Withdrawal by Subject                1 
Lost to Follow-up                4 
Physician Decision                5 
[1] 20 subjects completed the study.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Escitalopram Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.

Baseline Measures
   Escitalopram 
Overall Participants Analyzed 
[Units: Participants]
 30 
Age 
[Units: Participants]
 
<=18 years   0 
Between 18 and 65 years   30 
>=65 years   0 
Age 
[Units: Years]
Mean (Standard Deviation)
 43.6  (8.12) 
Gender 
[Units: Participants]
 
Female   10 
Male   20 
Region of Enrollment 
[Units: Participants]
 
United States   30 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A)   [ Time Frame: baseline and 7 weeks ]

2.  Primary:   Changes From Randomization to End of Treatment in Scores on the Beck Depression Inventory   [ Time Frame: baseline and 7 weeks ]

3.  Secondary:   Change From Randomization to End of Treatment in Scores for the Clinical Global Impression(CGI-S and CGI-I)   [ Time Frame: baseline and 7 weeks ]

4.  Secondary:   Change From Randomization to End of Treatment for Trail Making Tet (TMT)   [ Time Frame: baseline to 7 weeks ]

5.  Secondary:   Changes From Randomization to End of Treatment in Scores on the Mini Mental State Examination (MMSE)   [ Time Frame: baseline and 7 weeks ]

6.  Secondary:   Changes From Randomization to End of Treatment in Scores on the Sheehan Disability Scores (SDS)   [ Time Frame: baseline and 7 weeks ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information